Platinum-based chemotherapy in patients with advanced neuroendocrine carcinomas: an Italian retrospective multicenter analysis
#364
Introduction: Conventional chemotherapy has not yet a well defined role in well/moderately differentiated (WD) neuroendocrine carcinomas (NECs).
Aim(s): To assess the activity and toxicity of platinum-based chemotherapy in patients with advanced NECs. To evaluate the potential correlation between some clinical (primary site, somatostatin receptor expression, timing of the platinum-based regimen introduction) and biological factors (ERCC-1, grading and Ki67) with the clinical outcomes.
Materials and methods: The tumours were defined according to WHO 2000 and TNM 2006 classifications. Response rate (RR), time to progression (TTP), toxicity, and survival were calculated. The tissue tumour samples were centrally (IEO) analysed to detect Ki67, and excision repair cross-complementig group-1 (ERCC-1).
Conference:
Presenting Author:
Authors: SPADA F, SCARABELLI L, LORIZZO K, PELOSI G, BARBERIS M,
Keywords: neuroendocrine, ERCC1, Ki 67 ,
To read the full abstract, please log into your ENETS Member account.